Depending on the level of evidence provided and the methodology used, this advice is typically conveyed through a Guidance, a Systematic review or an Expert opinion.
The fifth meeting of the Hepatitis B and C Network aims to bring together experts from across the EU to discuss how Europe can improve its response to the epidemics of hepatitis B and C with a focus on surveillance, estimating prevalence, and the monitoring of response.
The ISIRV (International Society for Influenza and other Respiratory Virus Diseases) Epidemiology Group and ECDC are holding an influenza epidemiology meeting at ECDC in Stockholm 16-18 January 2019.
In a two-day meeting organised by ECDC and UNAIDS, representatives of 22 European countries discussed how to improve the delivery of HIV pre-exposure prophylaxis (PrEP) across Europe. The meeting brought together country delegates, PrEP users and community HIV advocates to seek ways to strengthen the provision and monitoring of PrEP.
The joint annual influenza surveillance meeting by ECDC and the WHO Regional Office for Europe took place on 6 - 8 June 2018 in Copenhagen, Denmark. Invited participants were epidemiological and virological surveillance experts nominated by national health authorities as well as representatives from international institutions, covering the 53 countries of the EU/EEA and the WHO European region. The meeting was by invitation only.
The meeting focused on the evidence base for the revision of the updated “Guide to public health measures to reduce the impact of influenza pandemics in Europe”, with a specific emphasis on non-pharmaceutical countermeasures for pandemic flu.
Influenza pandemics, whether mild, moderate or severe, affect a large proportion of the population and require a multisectoral response over several months or even years. For this reason, countries develop plans describing their strategies for responding to a pandemic supported by operational plans at national and subnational levels.
The conference addressed long-term effectiveness HIV of drugs, co-infections with tuberculosis or viral hepatitis and other co-morbidities, and most inequitable access to care across Europe